Truncated atrial natriuretic factor analogs retain full agonist activity

Area of Science:

• Biochemistry
• Pharmacology
• Endocrinology

Background:

• Atrial natriuretic peptide (ANP) is a hormone involved in regulating blood pressure and fluid balance.
• Native ANP (28 amino acids) has complex effects, including natriuresis, diuresis, vasodilation, and aldosterone inhibition.
• Truncated ANP analogs are being investigated for improved therapeutic properties.

Purpose of the Study:

• To synthesize and characterize novel truncated atrial natriuretic peptide (ANP) analogs.
• To evaluate the receptor binding affinity and agonist activity of these ANP analogs.
• To assess the in vivo natriuretic, hypotensive, and aldosterone-inhibiting effects of the lead analog.

Main Methods:

• Synthesis of disulfide-bonded cyclic peptides incorporating specific portions of native ANP.
• Measurement of receptor binding affinity (IC50).
• Assessment of agonist activity via cGMP biosynthesis in endothelial cells, aldosterone biosynthesis inhibition in rat adrenal cells, and in vivo natriuretic-hypotensive activity.

Main Results:

• Truncated ANP analogs incorporating C-terminal amino acids demonstrated full agonist activity.
• The lead compound, A-68828 (a tridecapeptide), exhibited a binding affinity of IC50 = 120 nM.
• A-68828 showed potent in vivo natriuretic activity (1/20-1/50 of ANP 1-28) and significantly inhibited aldosterone release (100% vs. 50% for ANP 1-28), with only mild hypotensive effects.

Conclusions:

• The inclusion of C-terminal amino acids converted ANP analogs into potent full agonists.
• A-68828 displays selective natriuretic activity with minimal hypotension, distinguishing it from native ANP.
• The selective natriuretic profile of A-68828 suggests potential clinical utility in treating acute renal failure.